Navigation Links
Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
Date:5/11/2011

NATICK, Mass., May 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the District Court for the District of Delaware found that Cordis Corporation owed Boston Scientific approximately $19.5 million for infringing its Jang patent, which covers intellectual property associated with coronary stent technologies.  The jury awarded $18.5 million in lost profits and $1 million in reasonable royalties to Boston Scientific.

Boston Scientific brought suit against Cordis for patent infringement in December 2009, shortly after the U.S. launch of Cordis' 2.25 mm Cypher® Stent.  On April 13, 2011 the Delaware Court ruled that, as a matter of law, Cordis infringed Boston Scientific's Jang patent and later found that Cordis' infringement was willful.  

"We are pleased to see the jury recognize the value of our intellectual property," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific.  "This is an important outcome in protecting our market position in small-vessel, drug-eluting stents against infringing products."

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our market position; intellectual property rights; litigation outcome; stent technology and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific Corporationerik.kopp@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
(Date:5/20/2016)... 2016 According to the 2016 home ... demand for affordable healthcare solutions as since the early 2000s, ... In countries like the US, the healthcare cost rose faster ... consumer price index inflation rate stood at an average of ... to 3.62% during the same time period. This can be ...
(Date:5/19/2016)... 2016 According to a new market research ... (U.S., Germany , France , ... and Japan )", published by MarketsandMarkets, The market ... CAGR of 13.9% from 2016 to 2021.      (Logo: ... data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, ... in the development of technological innovations that lead to broad-based healthcare solutions. , ...
(Date:5/24/2016)... ... 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on ... around the world who do not have access to a toilet, even when they’re on ... dread of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... Facility In Milwaukee , Out patient Services To Begin In June , Aloria ... is pleased to announce the opening of Aloria Milwaukee, its first treatment facility ...
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... May 24, 2016 , ... Dignity Health has announced ... The new facility is licensed under Dignity Health Arizona General Hospital, which opened ... Dignity Health in Arizona, said that the new facility will complement Dignity Health’s existing ...
Breaking Medicine News(10 mins):